![Marc M. Lemaître](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Marc M. Lemaître
Chief Executive Officer at Girindus America, Inc.
Marc M. Lemaître active positions
Companies | Position | Start | End |
---|---|---|---|
Girindus America, Inc.
![]() Girindus America, Inc. Pharmaceuticals: MajorHealth Technology Part of Nitto Denko Corp., Girindus America, Inc. provides oligonucleotide research and production services. The company is based in Cincinnati, OH. The CEO of the company is Marc M. Lemaître. Girindus America was acquired by Nitto Denko Avecia, Inc. from Girindus AG i.L. on January 30, 2013 for $12.60 million. | Chief Executive Officer | - | - |
Oligonucleotide Therapeutics Society, Inc.
![]() Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Director/Board Member | - | - |
Career history of Marc M. Lemaître
Former positions of Marc M. Lemaître
Companies | Position | Start | End |
---|---|---|---|
GIRINDUS AG IL | Chief Executive Officer | 2011-04-15 | 2013-01-10 |
Sales & Marketing | 2011-04-15 | 2013-01-10 |
Statistics
International
United States | 3 |
Germany | 2 |
Operational
Chief Executive Officer | 2 |
Sales & Marketing | 1 |
Director/Board Member | 1 |
Sectoral
Health Technology | 3 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 3 |
---|---|
Girindus AG i.L.
![]() Girindus AG i.L. Pharmaceuticals: MajorHealth Technology Girindus AG engages in the manufacturing and sale of pharmaceutical and chemical intermediate products. It also offers services including process development, analytical method development, radiolabeling, and manufacturing of active ingredients. The company was founded in 1974 and is headquartered in Hannover, Germany. | Health Technology |
Girindus America, Inc.
![]() Girindus America, Inc. Pharmaceuticals: MajorHealth Technology Part of Nitto Denko Corp., Girindus America, Inc. provides oligonucleotide research and production services. The company is based in Cincinnati, OH. The CEO of the company is Marc M. Lemaître. Girindus America was acquired by Nitto Denko Avecia, Inc. from Girindus AG i.L. on January 30, 2013 for $12.60 million. | Health Technology |
Oligonucleotide Therapeutics Society, Inc.
![]() Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Commercial Services |
- Stock Market
- Insiders
- Marc M. Lemaître
- Experience